KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation
Creators: name: Cif, L
name: Demailly, D
name: Lin, JP
name: Barwick, KE
name: Sa, M
name: Abela, L
name: Malhotra, S
name: Chong, WK
name: Steel, D
name: Sanchis-Juan, A
name: Ngoh, A
name: Trump, N
name: Meyer, E
name: Vasques, X
name: Rankin, J
name: Allain, MW
name: Applegate, CD
name: Isfahani, S Attaripour
name: Baleine, J
name: Balint, B
name: Bassetti, JA
name: Baple, EL
name: Bhatia, KP
name: Blanchet, C
name: Burglen, L
name: Cambonie, G
name: Seng, EC
name: Bastaraud, SC
name: Cyprien, F
name: Coubes, C
name: d'Hardemare, V
name: Study, Deciphering Developmental Disorders
name: Doja, A
name: Dorison, N
name: Doummar, D
name: Dy-Hollins, ME
name: Farrelly, E
name: Fitzpatrick, DR
name: Fearon, C
name: Fieg, EL
name: Fogel, BL
name: Forman, EB
name: Fox, RG
name: Consortium, Genomics England Research
name: Gahl, WA
name: Galosi, S
name: Gonzalez, V
name: Graves, TD
name: Gregory, A
name: Hallett, M
name: Hasegawa, H
name: Hayflick, SJ
name: Hamosh, A
name: Hully, M
name: Jansen, S
name: Jeong, SY
name: Krier, JB
name: Krystal, S
name: Kumar, KR
name: Laurencin, C
name: Lee, H
name: Lesca, G
name: François, LL
name: Lynch, T
name: Mahant, N
name: Martinez-Agosto, JA
name: Milesi, C
name: Mills, KA
name: Mondain, M
name: Morales-Briceno, H
name: BioResource, NIHR
name: Ostergaard, JR
name: Pal, S
name: Pallais, JC
name: Pavillard, F
name: Perrigault, PF
name: Petersen, AK
name: Polo, G
name: Poulen, G
name: Rinne, T
name: Roujeau, T
name: Rogers, C
name: Roubertie, A
name: Sahagian, M
name: Schaefer, E
name: Selim, L
name: Selway, R
name: Sharma, N
name: Signer, R
name: Soldatos, AG
name: Stevenson, DA
name: Stewart, F
name: Tchan, M
name: Network, Undiagnosed Diseases
name: Verma, IC
name: de Vries, BBA
name: Wilson, JL
name: Wong, DA
name: Zaitoun, R
name: Zhen, D
name: Znaczko, A
name: Dale, RC
name: de Gusmão, CM
name: Friedman, J
name: Fung, VSC
name: King, MD
name: Mohammad, SS
name: Rohena, L
name: Waugh, JL
name: Toro, C
name: Raymond, FL
name: Topf, M
name: Coubes, P
name: Gorman, KM
name: Kurian, MA
Publisher: name: arXiv
Year: 2025
Subjects: subject: Neurons and Cognition (q-bio.NC)
subject: FOS: Biological sciences
subject: FOS: Biological sciences

description: Heterozygous mutations in KMT2B are associated with an early-onset, progressive, and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor features at disease presentation, evolving through a caudocranial pattern into generalized dystonia, with prominent oromandibular, laryngeal, and cervical involvement. Although KMT2B-related disease is emerging as one of the most common causes of early-onset genetic dystonia, much remains to be understood about the full spectrum of the disease. We describe a cohort of 53 patients with KMT2B mutations, with detailed delineation of their clinical phenotype and molecular genetic features. We report new disease presentations, including atypical patterns of dystonia evolution and a subgroup of patients with a non-dystonic neurodevelopmental phenotype. In addition to the previously reported systemic features, our study has identified co-morbidities, including the risk of status dystonicus, intrauterine growth retardation, and endocrinopathies. Analysis of this study cohort (n = 53) in tandem with published cases (n = 80) revealed that patients with chromosomal deletions and protein-truncating variants had a significantly higher burden of systemic disease (with earlier onset of dystonia) than those with missense variants. Eighteen individuals had detailed longitudinal data available after insertion of deep brain stimulation for medically refractory dystonia. Median age at deep brain stimulation was 11.5 years (range: 4.5 to 37.0 years). Follow-up after deep brain stimulation ranged from 0.25 to 22 years. Significant improvement of motor function and disability (as assessed by the Burke-Fahn-Marsden Dystonia Rating Scales, BFMDRS-M and BFMDRS-D) was evident at 6 months, 1 year, and last follow-up (motor, P = 0.001, P = 0.004, and P = 0.012; disability, P = 0.009, P = 0.002, and P = 0.012).
description: PMID: 33150406; PMCID: PMC7719027